Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $387.15, moving -1.08% from the previous trading session. This change lagged the S&P 500's daily loss of 0.1%. Meanwhile, the Dow ...

Jupiter Endovascular announced today that its Vertex catheter received FDA 510(k) clearance for the insertion of endovascular ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

Vertex revenue grew 18% y/y in Q3 2022. The robust pipeline propels Vertex beyond the cystic fibrosis market. The stock price should rise as revenue rises through this decade. Vertex reported a strong ...

Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid pain reliever that could usher in a new era of nonaddictive therapy in the indication. As an oral ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year stint with Elon Musk.